To order this 330+ page report, please visit this link
Key Inclusions
§
A detailed assessment of the current market landscape of
targeted protein degradation-based therapeutics, providing information on drug
/ therapy developer(s) (such as year of establishment, company size and
location of headquarters), clinical study sponsor(s) and collaborator(s), type
of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic
tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic
modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase
of development (clinical, preclinical, and discovery stage) of product
candidates, target indication(s), key therapeutic area(s), type of target
protein(s), target enzyme(s) (if available), target signaling pathway (if
available), mechanism of action (if available), type of therapy
(monotherapy and combination therapy), route of administration (oral, intravenous
and others), and information on special drug designations (if any). In
addition, the chapter highlights the various technology platforms that are
being actively used for the development of targeted protein degraders.
§
Elaborate profiles of key players that are engaged in the
development of targeted protein degraders (shortlisted on the basis of phase
of development of pipeline products), featuring a brief overview of the
company, its financial information (if available), detailed descriptions
of their respective lead drug candidates, and an informed future outlook.
Additionally, each drug profile features information on the type of drug, route
of administration, target indications, current status of development and a
brief summary of its developmental history.
§
Brief tabulated profiles of industry players (shortlisted
on the basis of the number of pipeline products), featuring details on the
innovator company (such as year of establishment, location of headquarters,
number of employees, and key members of the executive team), recent
developments, along with descriptions of their respective drug candidates.
§
A detailed clinical trial analysis of completed, ongoing
and planned studies of various targeted protein degraders, highlighting
prevalent trends across various relevant parameters, such as current trial
status, trial registration year, enrolled patient population and regional
distribution of trials, type of protein degrader, phase of development, study
design, leading industry and non-industry players (in terms of number of
trials conducted), study focus, target therapeutic area, key indications,
and clinical endpoints.
§
An assessment of the relative experience of key opinion
leaders (KOLs) within this domain, (shortlisted based on their involvement
in various clinical studies), featuring detailed 2X2 matrices (based on
the strength and activeness of KOLs), a schematic world map representation
(highlighting the geographical locations of eminent scientists / researchers)
and an analysis evaluating the (relative) level of expertise of different KOLs,
based on parameters such as number of publications, number of citations,
participation in clinical trials, number of affiliations and strength of
professional network (based on information available on ResearchGate).
§
A detailed publication analysis of more than 210
peer-reviewed, scientific articles that have been published since 2017,
highlighting the research focus within the industry. It also highlights the key
trends observed across the publications, including information on novel protein
degraders, potential target proteins, target disease indications, and analysis
based on various relevant parameters, such as year of publication, and most
popular journals (in terms of number of articles published in the given time
period) within this domain.
§
An analysis of the partnerships that have been established
in the domain, over the period 2014-Q3 2019, covering research agreements,
product / technology licensing agreements, mergers / acquisitions, asset
purchase agreements, R&D and commercialization agreements, IP licensing
agreements, clinical trial agreements, product development agreements, and
other relevant deals.
§
An analysis of the investments made at various stages of
development, such as seed financing, venture capital financing, debt financing,
grants / awards, capital raised from IPOs and subsequent offerings, by
companies that are engaged in this field.
The report also features the
likely distribution of the current and forecasted opportunity across important
market segments, mentioned below:
§
Type of payment of
licensing agreements
§
Upfront payments
§
Milestone payments
§
Type of protein
degrader
§
Degronimids
§
PROTACs
§
SARDs / SERDs
§
Specific BET and DUB
inhibitors
§
Other protein degraders
§
Therapeutic area
§
Neurodegenerative
disorders
§
Oncological disorders
§
Other therapeutic
areas
§
Route of
administration
§
Oral
§
Intravenous
§
Other routes
§
Key geographical
region
§
North America
§
Europe
§
Asia-Pacific
To
request a sample pages, please visit this link
Key Questions Answered
§
What are the
prevalent R&D trends related to targeted protein degradation?
§
Which clinical
conditions can be treated using targeted protein degradation-based therapeutics?
§ What
are the most popular proteins being targeted by bifunctional degrader
molecules?
§
What are the key
challenges faced by stakeholders engaged in this domain?
§
What are the key
technology platforms that leverage the concept of targeted protein degradation?
§ Who
are the leading industry and non-industry players in this market?
§ What
are the contributions of big pharma players in this field?
§ What
are the key geographies where research on targeted protein degradation is being
conducted?
§ Who
are the key investors in this domain?
§ Who
are the key opinion leaders / experts in this field?
§ What
kind of partnership models are commonly adopted by industry stakeholders?
§ What
are the factors that are likely to influence the evolution of this upcoming market?
§
How is the current
and future market opportunity likely to be distributed across key market segments?
You
may also be interested in the following titles:
1.
DNA-Encoded
Libraries: Platforms and Services Market
2.
Global
Stem Cells Market: Focus on Clinical Therapies, 2020–2030
3.
The
Human Microbiome Market: Focus on Therapeutics (including gut-brain axis
targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition),
2019-2030
Contact Details:
Gaurav
Chaudhary
+1
(415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com